knowledge -WSS

knowledge

author：comprehensive 2025-09-02 08:16:53 - browse：4

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： House passes resolution saying Israel isn't a 'racist or apartheid state'

focus

WSS

ER docs worry over extreme heat as a 'mass casualty event'

Lilly’s weekly insulin works as well as daily products, new studies show

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

Oak Street deal isn't the answer to health care's woes

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

Wikipedia

knowledge

leisure time

Virginia high school admissions case could be legal follow

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

BioMarin wins approval for gene therapy to treat hemophilia A

Manchin plays down potential 3rd

Peter Hotez and the public health issue of online harassment

Galapagos to make CAR

How one medical school became remarkably diverse

What a koala virus tells us about the human genome

Activists slam private health insurers over coverage restrictions

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

hotspot

Galapagos to make CAR

Boston hospital trains restaurant workers on naloxone for overdoses

ALS treatment from Biogen, Ionis fails in study

Galapagos to make CAR

Johnson & Johnson sues to stop Medicare negotiation

Twill hunts for pharma partner to market its depression app

focus

Wikipedia

knowledge

knowledge